1. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Issue 2 (February 2016) Authors: Shaw, Alice T; Gandhi, Leena; Gadgeel, Shirish; Riely, Gregory J; Cetnar, Jeremy; West, Howard; Camidge, D Ross; Socinski, Mark A; Chiappori, Alberto; Mekhail, Tarek; Chao, Bo H; Borghaei, Hossein; Gold, Kathryn A; Zeaiter, Ali; Bordogna, Walter; Balas, Bogdana; Puig, Oscar; Henschel, Volkmar; Ou... Journal: Lancet oncology Issue: Volume 17:Issue 2(2016:Feb.) Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. (July 2018) Authors: Nishio, Makoto; Nakagawa, Kazuhiko; Mitsudomi, Tetsuya; Yamamoto, Nobuyuki; Tanaka, Tomohiro; Kuriki, Hiroshi; Zeaiter, Ali; Tamura, Tomohide Journal: Lung cancer Issue: Volume 121(2018) Page Start: 37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. (December 2020) Authors: Subbiah, Vivek; Paz-Ares, Luis; Besse, Benjamin; Moreno, Victor; Peters, Solange; Sala, María Angeles; López-Vilariño, José Antonio; Fernández, Cristian; Kahatt, Carmen; Alfaro, Vicente; Siguero, Mariano; Zeaiter, Ali; Zaman, Khalil; López, Rafael; Ponce, Santiago; Boni, Valentina; Arrondeau, Jen... Journal: Lung cancer Issue: Volume 150(2020) Page Start: 90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Issue 1 (January 2023) Authors: Aix, Santiago Ponce; Ciuleanu, Tudor Eliade; Navarro, Alejandro; Cousin, Sophie; Bonanno, Laura; Smit, Egbert F; Chiappori, Alberto; Olmedo, Maria Eugenia; Horvath, Ildiko; Grohé, Christian; Farago, Anna F; López-Vilariño, José Antonio; Cullell-Young, Martin; Nieto, Antonio; Vasco, Noelia; Gómez,... Journal: Lancet Issue: Volume 11:Issue 1(2023) Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37–40]. (June 2019) Authors: Nishio, Makoto; Nakagawa, Kazuhiko; Mitsudomi, Tetsuya; Yamamoto, Nobuyuki; Tanaka, Tomohiro; Kuriki, Hiroshi; Zeaiter, Ali; Tamura, Tomohide Journal: Lung cancer Issue: Volume 132(2019) Page Start: 160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study. Issue 11 (5th November 2021) Authors: Kristeleit, Rebecca; Moreno, Victor; Boni, Valentina; Guerra, Eva M; Kahatt, Carmen; Romero, Ignacio; Calvo, Emiliano; Basté, Neus; López-Vilariño, José A; Siguero, Mariano; Alfaro, Vicente; Zeaiter, Ali; Forster, Martin Journal: International journal of gynecological cancer Issue: Volume 31:Issue 11(2021) Page Start: 1428 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study. Issue 11 (5th October 2021) Authors: Kristeleit, Rebecca; Moreno, Victor; Boni, Valentina; Guerra, Eva M; Kahatt, Carmen; Romero, Ignacio; Calvo, Emiliano; Basté, Neus; López-Vilariño, José A; Siguero, Mariano; Alfaro, Vicente; Zeaiter, Ali; Forster, Martin Journal: International journal of gynecological cancer Issue: Volume 31:Issue 11(2021) Page Start: 1428 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects. Issue 3 (3rd October 2016) Authors: Morcos, Peter N.; Parrott, Neil; Banken, Ludger; Timpe, Carsten; Lindenberg, Marc; Guerini, Elena; Dall, Georgina; Bogman, Katrijn; Sturm, Carolina; Zeaiter, Ali; Martin‐Facklam, Meret; Phipps, Alex Journal: Clinical pharmacology in drug development Issue: Volume 6:Issue 3(2017) Page Start: 266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. (September 2017) Authors: Gandhi, Leena; Ou, Sai-Hong Ignatius; Shaw, Alice T.; Barlesi, Fabrice; Dingemans, Anne-Marie C.; Kim, Dong-Wan; Camidge, D. Ross; Hughes, Brett G.M.; Yang, James C.-H.; de Castro, Javier; Crino, Lucio; Léna, Hervé; Do, Pascal; Golding, Sophie; Bordogna, Walter; Zeaiter, Ali; Kotb, Ahmed; Gadgeel... Journal: European journal of cancer Issue: Volume 82(2017) Page Start: 27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial. (February 2015) Authors: de Marinis, Filippo; Vergnenegre, Alain; Passaro, Antonio; Dubos-Arvis, Catherine; Carcereny, Enric; Drozdowskyj, Ana; Zeaiter, Ali; Perez-Moreno, Pablo; Rosell, Rafael Journal: Future oncology Issue: Volume 11:Number 3(2015) Page Start: 421 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗